Joint bone spine · 2026
High-dose chemotherapy and transplantation of autologous CD34+ selected stem cells for progressive systemic sclerosis adjusted to cardiac and lung manifestation: An open-label, non-inferiority phase 2 trial.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pecher Ann-Christin, Koetter Ina, Peis Katrin, Klein Reinhild, Lengerke Claudia, Vogel Wichard, Krumm Patrick, Schmalzing Marc, Wirths Stefan, Henes Joerg
Аннотация
OBJECTIVES: Autologous hematopoietic stem cell transplantation (aHSCT) for systemic sclerosis (SSc) is an effective treatment strategy but carries a high treatment-related mortality (TRM). Consequently, patients with severe organ dysfunction have been excluded from previous randomized trials such as ASTIS. This study aimed to evaluate the feasibility and non-inferiority of a disease-manifestation - adapted chemotherapy protocol designed to mitigate toxicity to also treat patients who would have been ASTIS-ineligible.
METHODS: In this prospective, open-label, monocentric, phase II non-inferiority trial at the University Hospital Tübingen, Germany, patients with progressive SSc (disease duration≤6 years) were stratified by lung and cardiac involvement. Mobilization included 1500mg/m2 cyclophosphamide (CYC) for patients with inflammatory interstitial lung disease (iILD) versus 1000mg/m2 otherwise, both reduced compared to the ASTIS protocol. Conditioning comprised rabbit anti-thymocyte globulin (4×10mg/kg); patients without cardiac involvement additionally received CYC 4×50mg/kg. In those with cardiac involvement, CYC was reduced by 50% and thiotepa (2×5mg/kg) was added.
RESULTS: Between 09/2012 and 07/2022, 35 patients were treated (no iILD/cardiac involvement: n=14; iILD only: n=3; cardiac only: n=12; both: n=6). Three-year overall survival (OS) was 77%, meeting non-inferiority compared to EBMT registry data (80%). TRM within 100 days was 11% (n=4) in the whole group.
CONCLUSIONS: This adapted regimen showed comparable 3y-OS in patients with advanced organ involvement who would have been excluded from prior trials. While feasibility is demonstrated, aHSCT in this high-risk population remains associated with substantial risk, and efficacy cannot be definitively established. Further studies are warranted.
METHODS: In this prospective, open-label, monocentric, phase II non-inferiority trial at the University Hospital Tübingen, Germany, patients with progressive SSc (disease duration≤6 years) were stratified by lung and cardiac involvement. Mobilization included 1500mg/m2 cyclophosphamide (CYC) for patients with inflammatory interstitial lung disease (iILD) versus 1000mg/m2 otherwise, both reduced compared to the ASTIS protocol. Conditioning comprised rabbit anti-thymocyte globulin (4×10mg/kg); patients without cardiac involvement additionally received CYC 4×50mg/kg. In those with cardiac involvement, CYC was reduced by 50% and thiotepa (2×5mg/kg) was added.
RESULTS: Between 09/2012 and 07/2022, 35 patients were treated (no iILD/cardiac involvement: n=14; iILD only: n=3; cardiac only: n=12; both: n=6). Three-year overall survival (OS) was 77%, meeting non-inferiority compared to EBMT registry data (80%). TRM within 100 days was 11% (n=4) in the whole group.
CONCLUSIONS: This adapted regimen showed comparable 3y-OS in patients with advanced organ involvement who would have been excluded from prior trials. While feasibility is demonstrated, aHSCT in this high-risk population remains associated with substantial risk, and efficacy cannot be definitively established. Further studies are warranted.